Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel ...
https://www.google.com/url?rct=j&sa=t&url=https://www.globenewswire.com/news-release/2021/01/08/2155776/0/en/Ocugen-Inc-Regains-Compliance-with-Nasdaq-Bid-Price-Rule.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHr_UHKjMaLooUQP-NpS-GLuQUlUQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.